# Loyal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/loyal

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.loyal.com
- Total disclosed funding: $225M
- Latest round: Series C (Feb 11, 2026)
- Investors on record: 11

## About

Loyal, based in the US, focuses on developing innovative pharmaceutical solutions to enhance the health and longevity of dogs, with a particular emphasis on their lead product, LOY-002, an anti-aging treatment for senior dogs.Loyal is a company that specializes in veterinary pharmaceutical development, contributing to canine health with a focus on longevity. Founded in 2020, the company is headquartered in San Francisco, US. The latest funding round was a Series C, raising USD 100.00 mn on February 11, 2026, led by Age1 with participation from Baillie Gifford. Loyal has completed one deal to date and has raised a total of USD 100.00 mn.Loyal Animal Health, Inc. primarily focuses on developing innovative pharmaceutical solutions aimed at extending the healthy lifespan of dogs, particularly through their flagship product, LOY-002. This product is designed to function as an anti-aging pill, targeting various health issues commonly faced by senior dogs to improve their quality of life and longevity. The company is actively conducting clinical trials to validate the efficacy of LOY-002, with the first dog, named Boo, already dosed in their pivotal study. Loyal’s offerings also include LOY-001 and LOY-003, which cater to specific demographics of large dogs. The company targets a diverse customer base that includes veterinarians, dog owners, and pet health advocates across major markets, such as North America and Europe, emphasizing its commitment to improving canine health on a global scale.Loyal Animal Health generates revenue through a combination of direct-to-consumer sales and partnerships with veterinary clinics and pet health organizations. The revenue structure includes the distribution of LOY-002 and other products via licensed veterinarians who prescribe them to pet owners, thereby ensuring a direct line of communication between the company and its end users. This transactional framework facilitates a streamlined experience for customers seeking longevity solutions for their pets. Pricing strategies for individual products have been developed to reflect the unique benefits and research backing each offering, enhancing customer willingness to invest in their dogs' health. The company’s innovative approach to longevity positions it well within the pet health sector.In February 2026, Loyal raised USD 100 mn in Series C funding, which will be utilized to complete remaining regulatory approval steps, prepare for the launch of its lead dog medicine, and expand its team and distribution network. The company plans to introduce new products that enhance canine health, alongside a targeted expansion into new markets in North America and Europe. This strategic development aims to improve access to their innovative health solutions for a broader audience of pet owners and veterinary professionals.

## Funding rounds

- Series C, Feb 11, 2026, $100M — Baillie Gifford, Age1
- Series B, Oct 11, 2024, $22M — Valor Equity Partners, Collaborative Fund
- Series B, Mar 5, 2024, $76M — Bain Capital, Valor Equity Partners, Khosla Ventures, First Round Capital, Collaborative Fund, BoxGroup, Quiet Capital, The Todd & Rahul Angel Fund
- Series A, Sep 23, 2021, $27M — Khosla Ventures, First Round Capital, Collaborative Fund, BoxGroup, The Longevity Fund

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B
- First Round Capital (https://capitalatlas.ai/funds/first-round-capital) — Series A, Series B
- Collaborative Fund (https://capitalatlas.ai/funds/collaborative-fund) — Series A, Series B
- BoxGroup (https://capitalatlas.ai/funds/boxgroup) — Series A, Series B
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Series A
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B
- Valor Equity Partners (https://capitalatlas.ai/funds/valor-equity-partners) — Series B
- Quiet Capital (https://capitalatlas.ai/funds/quiet-capital) — Series B
- The Todd & Rahul Angel Fund (https://capitalatlas.ai/funds/the-todd-rahul-angel-fund) — Series B
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series C
- Age1 (https://capitalatlas.ai/funds/age1) — Series C